Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
AGM statement and recent progress
Destiny’s AGM included clinical and business development updates which we summarise below. In...
Read moreA year of progress, and addressing the future
Destiny’s full-year results for the year ending December 31 2023 included news of a strategic...
Read moreClinical Development Updates
Destiny Pharma has started the year with two important clinical development updates on its lead...
Read moreXF-73 is ‘The Real Deal’
With Destiny’s lead drug now licensed to Sebela Pharmaceuticals in preparation for its Phase 3...
Read moreInterim results: XF-73 3 – 0 The competition
There were few surprises in Destiny Pharma’s interim results as the recent achievements on its two...
Read moreManagement pieces in place
While the recent departure of its CEO may have come as a surprise to investors, the key parts of a...
Read moreXF-73 Momentum
Destiny’s recent business update noted the continued partnering interest on XF-73 Nasal – its now...
Read moreAGM update and CEO transition
Destiny’s AGM provided a summary of an eventful year that included the licensing of its lead Phase...
Read moreAnother string to the bow
Destiny have announced positive early results from its joint collaboration with SporeGen® on the...
Read moreNo surprises in results
While the costs and preparations for the Phase 3 studies on NTCD-M3 and XF-73 will continue over...
Read moreOnwards and upwards
Now that all the resolutions for Destiny’s fundraising that needed shareholder approval have been...
Read moreValidation well worth waiting for
After Destiny’s December trading update that led with draft terms and exclusivity being agreed for...
Read more- Prev
- 1 of 5 pages
- Next
Register to be first
Get research on the companies that interest you straight to your inbox
